Secondary prophylaxis of SBP in cirrhosis: trimethoprim-sulfamethoxazole vs. ciprofloxacin in a propensity-matched cohort [0.03%]
一项倾向匹配队列研究：SBP二级预防——复方新诺明与环丙沙星的对比
Mohamad Mahdi Osman,Omar T Sims,Dian J Chiang
Mohamad Mahdi Osman
Introduction and objectives: Spontaneous bacterial peritonitis (SBP1) is a common complication of cirrhosis. In the United States, inconsistent norfloxacin availability has shifted secondary SBP prophylaxis toward ciprofl...
Comment on "Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes" [0.03%]
关于“HABIT评分的建立与验证：一种实用而稳健的工具，用于预测不明原因转氨酶升高患者的肝脂肪变性”一文的述评
Yichao Mo,Xiaowen Su,Qinshou Chen et al.
Yichao Mo et al.
The role of inpatient palliative care consultation in end-stage liver disease: Too little, too late? [0.03%]
晚期肝病患者住院姑息治疗会诊的作用：太少且太迟吗？
Neha Wadhavkar,Joao Filipe G Monteiro,Kanika Malani et al.
Neha Wadhavkar et al.
Introduction and objectives: Patients with end-stage liver disease (ESLD) often experience high symptom burden and frequent hospitalizations. Despite studied benefits of palliative care consultation services (PCCS), use i...
Response to Letter to the Editor on "Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting" [0.03%]
关于“开展基于电子学习的医疗卫生试点项目——在公共初级医疗环境下开展针对丙型肝炎关怀的计算机基础培训及远程指导”的来信回复
Janus P Ong,Geohari L Hamoy,Eric D Ornos
Janus P Ong
PAI-1 as a modulator of the EMT-associated signaling pathway during HCV protein expression [0.03%]
HCV蛋白表达过程中PAI-1作为EMT相关信号通路调控分子的作用
Tania G Heredia-Torres,Alí F Ruiz-Higareda,Martin G Garcia-Juarez et al.
Tania G Heredia-Torres et al.
Introduction and objectives: Hepatitis C virus (HCV) infection promotes liver fibrosis through mechanisms involving epithelial-mesenchymal transition (EMT). Plasminogen activator inhibitor-1 (PAI-1), encoded by the SERPIN...
Quantifying long-term outcomes and risks for living liver donors: a review of the current global experience [0.03%]
评估活体肝脏捐献者的长期预后和风险：目前全球经验回顾
Ashwin Rammohan,Madhukar S Patel,Ramkiran Cherukuru et al.
Ashwin Rammohan et al.
Living donor liver transplantation is a critical treatment for end-stage liver disease, with numerous advantages over deceased donor liver transplant. However, living liver donors face potential long-term physical, psychological, and social...
Longitudinal health-related quality of life and associated factors in autoimmune liver diseases [0.03%]
自身免疫性肝病患者长期健康相关生活质量及影响因素分析
Dami Ko,Vilas Patwardhan,Natalia Rojas-Amaris et al.
Dami Ko et al.
Introduction and objectives: Autoimmune liver diseases (AILD), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), can significantly influence patients' healt...